Plasma ceramides highlighted in European Heart Journal

European Heart Journal recently highlighted Zora’s invention, new blood test that predicts cardiovascular events in patients with or without coronary artery disease. The test is based on quantification of plasma ceramides by mass spectrometry.

The test is believed to be sensitive enough that even individuals with normal levels of low-density lipoprotein (LDL) but still at risk may be identified. The test is in use at Mayo Clinic. The test can be found from Mayo’s test catalog with a name CERAM

Link to the original publication here.